What do systematic reviews say?

PUL vs sham

• Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 206 participants
  Moderate

PUL vs TURP

• Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 72 participants
  Low
• Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 69 participants
  Low

Pulmonary rehabilitation vs no pulmonary rehabilitation

• Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 194 participants
  Moderate

Pulmonary rehabilitation vs no pulmonary rehabilitation

• Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 89 participants
  Low

Pulmonary rehabilitation plus inspiratory muscle training vs pulmonary rehabilitation alone

• Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 908 participants
  Low
• Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 657 participants
  Very low

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

The review found no eligible studies for this question.

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 34 participants
  Low

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 238 participants
  Moderate

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 52 participants
  Low

Pulmonary rehabilitation vs no pulmonary rehabilitation

• Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 478 participants
  Moderate

Manipulation vs mobilisation

The review found no eligible studies for this question.

• Manipulation and mobilisation for neck pain contrasted against an inactive control or another active treatment 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Manipulation vs exercise

The review found no eligible studies for this question.

• Manipulation and mobilisation for neck pain contrasted against an inactive control or another active treatment 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pulmonary rehabilitation vs no pulmonary rehabilitation

• Pulmonary rehabilitation for interstitial lung disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 240 participants
  Low

Manipulation (cervical) vs oral medicine

The review found no eligible studies for this question.

• Manipulation and mobilisation for neck pain contrasted against an inactive control or another active treatment 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 267 participants
  Moderate

Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (long term)

The review found no eligible studies for this question.

• Duplex ultrasound for surveillance of lower limb revascularisation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Duplex ultrasound plus pulse palpation and arterial pressure index (ABI or TBI) vs pulse palpation plus arterial pressure index (ABI or TBI) (short term)

• Duplex ultrasound for surveillance of lower limb revascularisation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 594 participants
  Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25 participants
  Low

Manipulation (thoracic) vs inactive control

The review found no eligible studies for this question.

• Manipulation and mobilisation for neck pain contrasted against an inactive control or another active treatment 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

• Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 163 participants
  GRADE not reported